NSCLC | Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer
Faculty presentations from a CME symposium held during the ASTRO
2019 Annual Meeting. Featuring perspectives from moderator Dr Corey
J Langer and faculty members Drs Shruti Jolly, Billy Wiseman Loo Jr
and Jyoti D Patel:
Established Management Paradigms and Biologic Rationale for the
Evaluation of Immune Checkpoint Inhibitors for Patients with
Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Jolly
(00:00)
Integration of Immune Checkpoint Inhibition into the Management
of Locally Advanced NSCLC — Dr Langer (10:48)
Incidence, Recognition and Management of Immune-Mediated and
Other Toxicities with the Use of Anti-PD-L1 Antibody Therapy for
Locally Advanced Disease — Dr Patel (21:44)
Ongoing and Planned Clinical Trials of Immune Checkpoint
Inhibitors for Patients with Nonmetastatic NSCLC — Dr Loo
(36:37)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.